Experimental drug retatrutide reduces knee pain and body weight in clinical trials
Participants in two Phase III trials lost an average of one-quarter of their body weight and reported significant reductions in knee osteoarthritis pain.

Participants in two Northwestern University–led Phase III clinical trials involving more than 1,000 people lost about one-quarter of their body weight on average when taking the highest dose of retatrutide. The once-weekly injectable drug, developed by Eli Lilly, activates receptors for three distinct natural hormones.
A pooled analysis of the studies found that about two-thirds of participants receiving retatrutide experienced at least a 50% reduction in knee pain, compared with 38% of those receiving placebo. Participants also experienced reduced blood pressure, lower lipid levels, and less systemic inflammation.
"The findings are really saying for people who are overweight and have OA, if you lose a significant amount of weight with this treatment, there is a good chance that you're going to get a meaningful reduction in your knee pain," said corresponding author Dr. Thomas Schnitzer, a professor at Northwestern University Feinberg School of Medicine. He noted that losing weight reduces the load on the knees, which allows for increased function.
The results of the TRIUMPH-4 trial were presented by study co-author Philip Conaghan at the American College of Rheumatology annual meeting in Orlando, Florida, while the TRIUMPH-1-OA study results were presented the same day. Retatrutide resulted in 20%–25% weight loss, compared to 10%–20% weight loss typically seen with GLP-1 drugs like semaglutide or tirzepatide.
Dr. Schnitzer said the biggest unknown is whether retatrutide slows the progression of knee osteoarthritis enough to reduce the need for total joint replacement. He also noted that further research is needed to see if the drug can reduce painful knee osteoarthritis in people who are not overweight.
Key facts
- High doses of retatrutide led to an average weight loss of approximately one-quarter of body weight in Phase III trials.
- About two-thirds of retatrutide recipients saw at least a 50% reduction in knee pain.
- Retatrutide is a once-weekly injectable that activates three distinct natural hormone receptors.
Three perspectives
Neutral
Two Phase III clinical trials found that the experimental drug retatrutide leads to significant weight loss and reduced knee pain in adults with obesity and osteoarthritis.
Positive
Participants receiving the highest dose of retatrutide experienced weight loss of 20%–25% and significant reductions in knee pain, blood pressure, and inflammation.
Negative
It is unknown if the drug can slow the progression of knee osteoarthritis enough to prevent the need for total joint replacement.
Your week in news, every Wednesday
The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.